News

Richards describes the utility of different NITs in primary and specialty care for risk-stratifying patients with MASH and fibrosis.

Multiple biomarkers and clinical background factors were linked to improved clinical outcomes after dupilumab therapy for AD.

In this analysis, an increased risk of allergy and eczema was associated with bread and thiamine intake increases during pregnancy.

A new study found cannabis-containing cream may be effective at alleviating itch in patients with chronic kidney disease (CKD)-associated pruritus with no adverse events.

Solomon explains how to navigate the growing Crohn disease treatment armamentarium and the importance of treatment positioning.

MYL-1701P showed equivalent efficacy, with comparable safety and immunogenicity, to reference aflibercept in the Phase 3 INSIGHT trial.

These data highlighted dupilumab’s potential as a means to break the ‘itch–scratch cycle’ in those with chronic prurigo, with disease remission induced in a subset.

In an interview, lead investigator Lauren Moran, MD, shared how the results inform clinical practice on safe amphetamine dosing.

Iordache reviews complications of diagnosing hepatobiliary disease in pregnancy and explains how these patients typically present.

The agency's designation was granted to plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.

The APAC Recap is a new multimedia series created through a partnership between APAC and HCPLive where members of the Academy of Physician Associates have peer-to-peer discussions centered around recent scientific congresses and meetings.

This analysis may help to inform research evaluating the value of obstructive sleep apnea treatments designed to minimize cardiovascular risk as well as related deaths among older patients.

A new study highlights the need for caution when prescribing high-dose amphetamines (≥ 30 mg) due to their psychosis and mania risk.

Martinez de Andino reviews key considerations for the management of DGBI with brain-gut behavioral therapy and neuromodulators.

A follow-up to an earlier episode, this episode features a deep dive into the hosts experience with the Dexcom Stelo sensor.

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.

Pre-pregnancy overweight and obesity were not linked to an increased prevalence of iron deficiency or anemia during pregnancy in a US population.

In this survey, investigators sought to develop a definition for eczema flare which was patient-centered and based upon consensus.

In a recently published Viewpoint, the authors stress the importance of dermatologists staying updated on prescription cost-saving programs and their impact on patient care.

In this episode, hosts discuss availability of the Abbott Lingo CGM and Embecta’s announcement of FDA clearance for their tubeless patch pump with a 300-unit insulin reservoir.

These data may provide invaluable insights, given the lack of reliable methods for identifying newborns with increased risk of developing eczema.

A real-world post-authorization safety study identified no new safety signals compared with the phase 2/3 clinical trial of rpFVIII for acquired hemophilia A.

Low birth weight and being small for gestational age were linked to a greater risk of developing pediatric-onset MASLD and progressive liver disease.

Lifetime statin treatment increased quality-of-life-adjusted survival in men and women aged ≥70 years with and without previous CVD in the United Kingdom.

These findings also highlight that an early response to alopecia areata treatment can be identified with trichoscopy.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

Findings highlight disease burden and ongoing unmet needs in patients with IBS-C and IBS-D, suggesting the benefit of prescription medications on rates of satisfaction and symptom control.

Deepak Bhatt, MD, MPH, MBA, discusses the results of a prespecified analysis of the EMPACT-MI trial examining the effect across the spectrum of baseline kidney function.